Covered recipient · General Payments record
PHILIP KURIAKOSE
General Payments · PY2018–2024
$115,714.42
- Reported across 94 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2024 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Consulting Fee | $21,075.25 | 5 |
| Travel and Lodging | $680.50 | 4 |
| Food and Beverage | $474.26 | 2 |
By paying entity
PY2024 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Novo Nordisk AS | $12,781.01 | 7 |
| GENZYME CORPORATION | $3,449.00 | 2 |
| NOVARTIS PHARMACEUTICALS CORPORATION | $3,200.00 | 1 |
| ADC Therapeutics America, Inc. | $2,800.00 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2024 (11)
Sorted by paying entity, then date · as published by CMS
Program year 2024 201820192020202120222023
Record-level detail is published for PY2024; earlier years are summarised in
“By program year”.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| ADC Therapeutics America, Inc. | $2,800.00 | 03/08/2024 | Consulting Fee | Undisputed | 01/23/2026 | 1121193351 | CMS |
| GENZYME CORPORATION | $125.00 | 03/12/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1139677839 | CMS |
| GENZYME CORPORATION | $3,324.00 | 03/12/2024 | Consulting Fee | Undisputed | 01/23/2026 | 1139677841 | CMS |
| Novartis Pharmaceuticals Corporation | $3,200.00 | 06/18/2024 | Consulting Fee | Undisputed | 01/23/2026 | 1087140172 | CMS |
| Novo Nordisk Inc | $1,190.00 | 08/07/2024 | Consulting Fee | Undisputed | 01/23/2026 | 1097693606 | CMS |
| Novo Nordisk Inc | $227.33 | 08/08/2024 | Travel and Lodging | Undisputed | 01/23/2026 | 1096657894 | CMS |
| Novo Nordisk Inc | $29.42 | 08/08/2024 | Travel and Lodging | Undisputed | 01/23/2026 | 1097494195 | CMS |
| Novo Nordisk Inc | $366.80 | 08/08/2024 | Travel and Lodging | Undisputed | 01/23/2026 | 1097497312 | CMS |
| Novo Nordisk Inc | $10,561.25 | 08/08/2024 | Consulting Fee | Undisputed | 01/23/2026 | 1097498354 | CMS |
| Novo Nordisk Inc | $349.26 | 08/08/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1097499092 | CMS |
| Novo Nordisk Inc | $56.95 | 08/08/2024 | Travel and Lodging | Undisputed | 01/23/2026 | 1097499148 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2018, 2019, 2020, 2021, 2022, 2023, 2024
- Source files
- Dataset page · Bulk file · PY2018 , PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024
- Generated from
- OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.